Department of Surgical Oncology and HIPEC, Athens Medical Centre, Athens, Greece.
Department of Surgical Oncology and HIPEC, European Interbalkan Medical Centre, Thessaloniki, Greece.
J Surg Oncol. 2021 Feb;123(2):630-637. doi: 10.1002/jso.26280. Epub 2020 Oct 30.
Newly diagnosed advanced-stage ovarian cancer patients are treated with neoadjuvant chemotherapy, primary or intermediate cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study is to evaluate the optimal timing of cytoreduction plus HIPEC for advanced ovarian cancer patients.
Advanced ovarian cancer patients treated with cytoreductive surgery plus HIPEC at three different hospitals between 2005 and 2019 were subgrouped regarding their time of management with cytoreduction plus HIPEC, upfront or intermediate. We retrospectively assessed the overall survival (OS), the progression-free survival (PFS), and the disease-free survival (DFS) of these groups.
A total of 112 ovarian cancer patients were contained. Of whom, 47 patients were in the upfront group with 24 (51.1%) to be alive, while 65 patients were included in the intermediate group with 34 (52.3%) to be alive. OS (48 vs. 30 months) and DFS (42 vs. 20 months) indicated no significant difference. Although the same median PFS was observed in both groups (10 months), a higher mean PFS was observed in the upfront group (11.9 vs. 9 months, p = 0.023).
The treatment of advanced ovarian cancer patients with upfront cytoreductive surgery plus HIPEC is feasible with the same survival results. Further, larger prospective studies need to verify our results.
新诊断的晚期卵巢癌患者接受新辅助化疗、原发性或中间减瘤手术和腹腔内热灌注化疗（HIPEC）治疗。本研究旨在评估晚期卵巢癌患者行细胞减灭术加 HIPEC 的最佳时机。
2005 年至 2019 年，在三家医院接受细胞减灭术加 HIPEC 治疗的晚期卵巢癌患者，根据细胞减灭术加 HIPEC 的管理时间分为 upfront 或 intermediate 组。我们回顾性评估了这些组的总生存期（OS）、无进展生存期（PFS）和无病生存期（DFS）。
共纳入 112 例卵巢癌患者。其中 upfront 组 47 例，存活 24 例（51.1%）；intermediate 组 65 例，存活 34 例（52.3%）。OS（48 个月 vs. 30 个月）和 DFS（42 个月 vs. 20 个月）无显著差异。尽管两组的中位 PFS 相同（10 个月），但 upfront 组的平均 PFS 更高（11.9 个月 vs. 9 个月，p = 0.023）。
对于晚期卵巢癌患者， upfront 细胞减灭术加 HIPEC 的治疗是可行的，且生存结果相同。需要进一步开展更大规模的前瞻性研究来验证我们的结果。
